Li Bian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Bian has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Yu Zhang
Department of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
6 shared publicationsFangfang Li
Department of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
5 shared publicationsMuye Li
Department of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
4 shared publicationsGuiyun Li
Department of Pathology, The First Affliated Hospital of Kunming Medical University, Kunming 650032, China
3 shared publicationsXiaofang Wang
Department of Pathology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
3 shared publicationsXuan Luo
Department of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
3 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in Respiratory Research
FBXL18 ubiquitinates and degrades MDFI to suppress Wnt/β-catenin signaling and reverse cisplatin resistance in lung cancer
- 12 September 2026
- Published by Springer Nature in Respiratory Research
Open AccessFBXL18 ubiquitinates and degrades MDFI to suppress Wnt/β-catenin signaling and reverse cisplatin resistance in lung cancer
- Open Access
- 6 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Using single-cell and transcriptome data to identify prognostic genes associated with SUMO-ylation and their molecular regulatory mechanisms in breast cancer
Dysregulation of small ubiquitin-like modifier ylation (SUMO-ylation) is closely associated with the development of different types of cancers. Growing evi
- 6 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessUsing single-cell and transcriptome data to identify prognostic genes associated with SUMO-ylation and their molecular regulatory mechanisms in breast cancer
Dysregulation of small ubiquitin-like modifier ylation (SUMO-ylation) is closely associated with the development of different types of cancers. Growing evi
- Open Access
- 30 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Driver gene-specific prevalence and incidence of brain metastases in non-small cell lung cancer: a meta-analysis encompassing all disease stages
Background: Brain metastases (BM) in non-small cell lung cancer (NSCLC) are associated with a poor prognosis. Identifying relevant genomic alterations can facilitate the targeting of therapies. We conducted a systematic review and meta-analysis to assess the prevalence and incidence of these alterations in NSCLC patients. Methods: PubMed, Embase and WOS were searched, from January 2000 to February 2024 using "lung", "met" and "incidence" as search phrases. We obtained data on the prevalence at diagnosis and the annual incidence of new BM in patients with EGFR, ALK, KRAS, and other genetic alterations. The pooled prevalence and incidence rates were calculated using a random effects model. This study is registered with PROSPERO (CRD42023491178). Results: A total of 120 articles were included in the analysis. Prevalence data were derived from 94 studies (17,458 patients), while incidence data were obtained from 95 studies (13,323 patients). The pooled prevalence of BM at diagnosis was found to be 28.8% (95% [CI]: 0.263–0.313). This prevalence was highest among patients who were ALK-positive (31.6%) or had EGFR-positive (29.4%). The incidence rates were observed to be 0.086 in the EGFR group (95% CI 0.045–0.131), 0.062 in the ALK group (95% CI 0.003–0.122), 0.057 in the KRAS group (95% CI 0.000–0.188), 0.064 in the ROS1 group (95% CI 0.000–0.162), and 0.055 in the RET group (95% CI 0.000–0.224). Interpretation: Comprehensive meta-analyses indicate prevalence and incidence of BM are higher in patients with specific genomic alterations and advanced disease. Brain imaging and targeted therapies for brain penetrance are important.
- 30 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Open AccessDriver gene-specific prevalence and incidence of brain metastases in non-small cell lung cancer: a meta-analysis encompassing all disease stages
Background: Brain metastases (BM) in non-small cell lung cancer (NSCLC) are associated with a poor prognosis. Identifying relevant genomic alterations can facilitate the targeting of therapies. We conducted a systematic review and meta-analysis to assess the prevalence and incidence of these alterations in NSCLC patients. Methods: PubMed, Embase and WOS were searched, from January 2000 to February 2024 using "lung", "met" and "incidence" as search phrases. We obtained data on the prevalence at diagnosis and the annual incidence of new BM in patients with EGFR, ALK, KRAS, and other genetic alterations. The pooled prevalence and incidence rates were calculated using a random effects model. This study is registered with PROSPERO (CRD42023491178). Results: A total of 120 articles were included in the analysis. Prevalence data were derived from 94 studies (17,458 patients), while incidence data were obtained from 95 studies (13,323 patients). The pooled prevalence of BM at diagnosis was found to be 28.8% (95% [CI]: 0.263–0.313). This prevalence was highest among patients who were ALK-positive (31.6%) or had EGFR-positive (29.4%). The incidence rates were observed to be 0.086 in the EGFR group (95% CI 0.045–0.131), 0.062 in the ALK group (95% CI 0.003–0.122), 0.057 in the KRAS group (95% CI 0.000–0.188), 0.064 in the ROS1 group (95% CI 0.000–0.162), and 0.055 in the RET group (95% CI 0.000–0.224). Interpretation: Comprehensive meta-analyses indicate prevalence and incidence of BM are higher in patients with specific genomic alterations and advanced disease. Brain imaging and targeted therapies for brain penetrance are important.
- Open Access
- 20 April 2024
- Vol. 27 (4) , 245-256
[Role of COX-2/PGE2/EP4 Axis-induced Macrophage Functional Activation in NSCLC Development].
Tumor microenvironment (TME) is one of the important factors in tumorigenesis and progression, in which tumor-associated macrophages (TAMs) play an important role in non-small cell lung cancer (NSCLC) progression. However, the mechanism of TAMs in NSCLC progression remains unclear, so this study aimed to investigate the role of TAMs in NSCLC progression and to find potential therapeutic targets. Gene Expression Profiling Interactive Analysis (GEPIA) database was used to analyze the expression of prostaglandin E2 receptor 4 (EP4) mRNA in NSCLC and normal lung tissues; the protein expression levels of cyclooxygenase-2 (COX-2), EP4, cluster of differentiation 86 (CD86), CD163 and CD31 were detected by immunohistochemistry (IHC) in 120 NSCLC tissues and 24 paracancerous tissues specimens. The nude mouse lung adenocarcinoma cell A549 and macrophage RAW264.7 co-transplanted tumor model was established. And the samples were collected by gavage with EP4 inhibitor E7046, and then stained with hematoxylin-eosin (HE), IHC, and immunofluorescence (IF), and then detected by Western blot for the epithelial mesenchymal transformation (EMT) of the tumor tissues of the nude mice in each group. Western blot was used to detect the expressions of EMT related protiens in each group of nude mice; full-length transcriptome sequencing was used to screen the key genes causing liver metastasis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed. EP4 mRNA expression level in NSCLC tissues was generally lower than that in normal lung tissues (P<0.05); COX-2, EP4, CD163, CD31 proteins were differentially expressed in NSCLC tissues and adjacent tissues, and differences were observed in many clinicopathological parameters of NSCLC patients; RAW264.7 shortened the latency period of tumorigenesis of A549 and promoted the proliferation of tumors and liver metastasis of tumors, and E7046 could reduce tumor cell proliferation activity, tumor tissue vascular density and M2-type macrophage infiltration in nude mice; IF staining showed that macrophages were mainly distributed around the metastatic foci of tumors; Western blot results showed that compared with A549 alone transplantation group, the relative expression of E-cadherin protein in tumor tissues of mice in A549 and RAW264.7 co-transplantation group was significantly decreased, and the difference was statistically significant (P0.05); the main pathways enriched in the differential genes of the full-length transcriptome were the PI3K-AKT and MAPK signaling pathways. During NSCLC development, the COX-2/PGE2/EP4 axis may promote tumor progression by inducing macrophage functional activation, and EP4 may be a potential new target for tumor immunotherapy. This study provides new perspectives and ideas for in-depth exploration of the mechanisms of NSCLC development, as well as a theoretical basis for the development of new therapeutic strategies for NSCLC.
- 20 April 2024
- Vol. 27 (4) , 245-256
Open Access[Role of COX-2/PGE2/EP4 Axis-induced Macrophage Functional Activation in NSCLC Development].
Tumor microenvironment (TME) is one of the important factors in tumorigenesis and progression, in which tumor-associated macrophages (TAMs) play an important role in non-small cell lung cancer (NSCLC) progression. However, the mechanism of TAMs in NSCLC progression remains unclear, so this study aimed to investigate the role of TAMs in NSCLC progression and to find potential therapeutic targets. Gene Expression Profiling Interactive Analysis (GEPIA) database was used to analyze the expression of prostaglandin E2 receptor 4 (EP4) mRNA in NSCLC and normal lung tissues; the protein expression levels of cyclooxygenase-2 (COX-2), EP4, cluster of differentiation 86 (CD86), CD163 and CD31 were detected by immunohistochemistry (IHC) in 120 NSCLC tissues and 24 paracancerous tissues specimens. The nude mouse lung adenocarcinoma cell A549 and macrophage RAW264.7 co-transplanted tumor model was established. And the samples were collected by gavage with EP4 inhibitor E7046, and then stained with hematoxylin-eosin (HE), IHC, and immunofluorescence (IF), and then detected by Western blot for the epithelial mesenchymal transformation (EMT) of the tumor tissues of the nude mice in each group. Western blot was used to detect the expressions of EMT related protiens in each group of nude mice; full-length transcriptome sequencing was used to screen the key genes causing liver metastasis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed. EP4 mRNA expression level in NSCLC tissues was generally lower than that in normal lung tissues (P<0.05); COX-2, EP4, CD163, CD31 proteins were differentially expressed in NSCLC tissues and adjacent tissues, and differences were observed in many clinicopathological parameters of NSCLC patients; RAW264.7 shortened the latency period of tumorigenesis of A549 and promoted the proliferation of tumors and liver metastasis of tumors, and E7046 could reduce tumor cell proliferation activity, tumor tissue vascular density and M2-type macrophage infiltration in nude mice; IF staining showed that macrophages were mainly distributed around the metastatic foci of tumors; Western blot results showed that compared with A549 alone transplantation group, the relative expression of E-cadherin protein in tumor tissues of mice in A549 and RAW264.7 co-transplantation group was significantly decreased, and the difference was statistically significant (P0.05); the main pathways enriched in the differential genes of the full-length transcriptome were the PI3K-AKT and MAPK signaling pathways. During NSCLC development, the COX-2/PGE2/EP4 axis may promote tumor progression by inducing macrophage functional activation, and EP4 may be a potential new target for tumor immunotherapy. This study provides new perspectives and ideas for in-depth exploration of the mechanisms of NSCLC development, as well as a theoretical basis for the development of new therapeutic strategies for NSCLC.
- Open Access
- 30 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma
Lung cancer, specifically the histological subtype lung adenocarcinoma (LUAD), has the highest global occurrence and fatality rate. Extensive research has indicated that RNA alterations encompassing m6A, m5C, and m1A contribute actively to tumorigenesis, drug resistance, and immunotherapy responses in LUAD. Nevertheless, the absence of a dependable predictive model based on m6A/m5C/m1A-associated genes hinders accurately predicting the prognosis of patients diagnosed with LUAD. In this study, we collected patient data from The Cancer Genome Atlas (TCGA) and identified genes related to m6A/m5C/m1A modifications using the GeneCards database. The “ConsensusClusterPlus” R package was used to produce molecular subtypes by utilizing genes relevant to m6A/m5C/m1A identified through differential expression and univariate Cox analyses. An independent prognostic factor was identified by constructing a prognostic signature comprising six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8). Poor overall survival and elevated expression of human leukocyte antigens and immune checkpoints were correlated with higher risk scores. We examined the associations between the sets of genes regulated by m6A/m5C/m1A and the risk model, as well as the immune cell infiltration, using algorithms such as ESTIMATE, CIBERSORT, TIMER, ssGSEA, and exclusion (TIDE). Moreover, we compared tumor stemness indices (TSIs) by considering the molecular subtypes related to m6A/m5C/m1A and risk signatures. Analyses were performed based on the risk signature, including stratification, somatic mutation analysis, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In summary, we developed a prognostic signature consisting of six genes that have the potential for prognostication in patients with LUAD and the design of personalized treatments that could provide new versions of personalized management for these patients.
- 30 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Open AccessIdentification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma
Lung cancer, specifically the histological subtype lung adenocarcinoma (LUAD), has the highest global occurrence and fatality rate. Extensive research has indicated that RNA alterations encompassing m6A, m5C, and m1A contribute actively to tumorigenesis, drug resistance, and immunotherapy responses in LUAD. Nevertheless, the absence of a dependable predictive model based on m6A/m5C/m1A-associated genes hinders accurately predicting the prognosis of patients diagnosed with LUAD. In this study, we collected patient data from The Cancer Genome Atlas (TCGA) and identified genes related to m6A/m5C/m1A modifications using the GeneCards database. The “ConsensusClusterPlus” R package was used to produce molecular subtypes by utilizing genes relevant to m6A/m5C/m1A identified through differential expression and univariate Cox analyses. An independent prognostic factor was identified by constructing a prognostic signature comprising six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8). Poor overall survival and elevated expression of human leukocyte antigens and immune checkpoints were correlated with higher risk scores. We examined the associations between the sets of genes regulated by m6A/m5C/m1A and the risk model, as well as the immune cell infiltration, using algorithms such as ESTIMATE, CIBERSORT, TIMER, ssGSEA, and exclusion (TIDE). Moreover, we compared tumor stemness indices (TSIs) by considering the molecular subtypes related to m6A/m5C/m1A and risk signatures. Analyses were performed based on the risk signature, including stratification, somatic mutation analysis, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In summary, we developed a prognostic signature consisting of six genes that have the potential for prognostication in patients with LUAD and the design of personalized treatments that could provide new versions of personalized management for these patients.
- 1 February 2024
- Vol. 42 (1) , 126-132
腮腺透明细胞型嗜酸细胞腺瘤1例
腮腺嗜酸细胞腺瘤是一种涎腺良性肿瘤,其发病率低,既往文献少有报道,而以透明细胞为主型的嗜酸细胞腺瘤病例报道更为少见。该肿瘤临床表现及影像学检查无特异性,在诊疗中与涎腺其他肿瘤如嗜酸细胞癌以及转移性肾透明细胞癌鉴别困难,易导致误诊误治。为探讨涎腺透明细胞为主型嗜酸细胞腺瘤的诊断和治疗,提高对该肿瘤的临床病理组织学特征的认识,现报告1例腮腺透明细胞为主型嗜酸细胞腺瘤病例,并对以往相关文献进行回顾复习。
- 1 February 2024
- Vol. 42 (1) , 126-132
腮腺透明细胞型嗜酸细胞腺瘤1例
腮腺嗜酸细胞腺瘤是一种涎腺良性肿瘤,其发病率低,既往文献少有报道,而以透明细胞为主型的嗜酸细胞腺瘤病例报道更为少见。该肿瘤临床表现及影像学检查无特异性,在诊疗中与涎腺其他肿瘤如嗜酸细胞癌以及转移性肾透明细胞癌鉴别困难,易导致误诊误治。为探讨涎腺透明细胞为主型嗜酸细胞腺瘤的诊断和治疗,提高对该肿瘤的临床病理组织学特征的认识,现报告1例腮腺透明细胞为主型嗜酸细胞腺瘤病例,并对以往相关文献进行回顾复习。
- 11 January 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 259 (Pt 2) , 129184
DTL promotes head and neck squamous cell carcinoma progression by mediating the degradation of ARGLU1 to regulate the Notch signaling pathway
- 11 January 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 259 (Pt 2) , 129184
DTL promotes head and neck squamous cell carcinoma progression by mediating the degradation of ARGLU1 to regulate the Notch signaling pathway
- Open Access
- 29 November 2023
- Published by Springer Nature in Research Square
Identification of Molecular Subtypes and a Prognostic Signature Based on m6A/m5C/m1A-Related Genes in Lung adenocarcinoma
Lung adenocarcinoma (LUAD) is the most common histological type of lung cancer and has high incidence and mortality rates worldwide. Increasing evidence suggests that RNA modifications involving m6A, m5C, and m1A play a vital part in tumorigenesis, drug resistance and immunotherapy. However, there is no reliable model according to m6A/m5C/m1A-related genes to predict the patients’ prognosis in LUAD. We obtained patient data from The Cancer Genome Atlas (TCGA) and captured m6A/m5C/m1A-related genes from the GeneCards database. The “ConsensusClusterPlus” R package was used to generate molecular subtypes based on m6A/m5C/m1A-related genes obtained by differential expression analysis and univariate Cox analysis. We constructed a prognostic signature consisting of six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8), which was identified as an independent prognostic factor. Higher risk scores were associated with poorer overall survival and increased expression of human leukocyte antigen and immune checkpoints. The relationships between m6A/m5C/m1A regulated gene subsets and risk model and immune cell infiltration were analyzed using estimate, CIBERSORT, TIMER, ssGSEA algorithms and exclusion (TIDE). The tumour stemness indices (TSIs) were also compared based on m6A/m5C/m1A -related molecular subtypes and the risk signature. Based on the risk signature, various analyses were conducted including stratification, somatic mutation, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In conclusion, we constructed a six-gene prognostic signature that could be useful for prognostication in LUAD patients and designing personalized treatments, which could provide new versions of personalized management for these patients.
- 29 November 2023
- Published by Springer Nature in Research Square
Open AccessIdentification of Molecular Subtypes and a Prognostic Signature Based on m6A/m5C/m1A-Related Genes in Lung adenocarcinoma
Lung adenocarcinoma (LUAD) is the most common histological type of lung cancer and has high incidence and mortality rates worldwide. Increasing evidence suggests that RNA modifications involving m6A, m5C, and m1A play a vital part in tumorigenesis, drug resistance and immunotherapy. However, there is no reliable model according to m6A/m5C/m1A-related genes to predict the patients’ prognosis in LUAD. We obtained patient data from The Cancer Genome Atlas (TCGA) and captured m6A/m5C/m1A-related genes from the GeneCards database. The “ConsensusClusterPlus” R package was used to generate molecular subtypes based on m6A/m5C/m1A-related genes obtained by differential expression analysis and univariate Cox analysis. We constructed a prognostic signature consisting of six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8), which was identified as an independent prognostic factor. Higher risk scores were associated with poorer overall survival and increased expression of human leukocyte antigen and immune checkpoints. The relationships between m6A/m5C/m1A regulated gene subsets and risk model and immune cell infiltration were analyzed using estimate, CIBERSORT, TIMER, ssGSEA algorithms and exclusion (TIDE). The tumour stemness indices (TSIs) were also compared based on m6A/m5C/m1A -related molecular subtypes and the risk signature. Based on the risk signature, various analyses were conducted including stratification, somatic mutation, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In conclusion, we constructed a six-gene prognostic signature that could be useful for prognostication in LUAD patients and designing personalized treatments, which could provide new versions of personalized management for these patients.
- Open Access
- 20 October 2023
- Vol. 26 (10) , 732-740
瘦素/ERK信号在云锡矿粉诱导大鼠II型肺泡上皮细胞转化中的作用
目前,云南个旧锡矿有大量矿工从事开采工作,这种职业环境与接触粉尘颗粒、重金属、多环芳烃和放射性氡有关,大大增加了患肺癌的风险。本研究旨在探讨在云锡矿粉诱导大鼠肺泡II型上皮细胞(immortalized rat alveolar cells type II, RLE-6TN)恶性转化过程中,瘦素(leptin)及其介导的细胞外调节蛋白激酶(extracellular regulated protein kinase, ERK)信号通路所起的作用。 采用200 μg/mL的云锡矿粉隔代毒染RLE-6TN至第9代,建立毒染细胞模型,命名为R200细胞,正常培养组命名为R细胞,通过Western blot法检测两种细胞leptin受体的表达情况。通过MTT法筛选出leptin及丝裂原活化蛋白激酶激酶(mitogen-activated protein kinase kinase, MEK)抑制剂(U0126)对R200细胞的最佳作用浓度。自第20代起,将R组、R200组细胞分别与leptin及MEK抑制剂U0126共培养,对各组细胞的形态改变进行观察,并利用苏木素-伊红(hematoxylin-eosin, HE)染色技术鉴别第40代细胞的形态学差异,通过刀豆凝集素A(concanavalin A, ConA)及锚着独立性生长实验法检测细胞恶性转化情况。通过Western blot法检测leptin作用后上皮细胞ERK信号通路的变化。 ng/mL时,其促增殖效应最为显著,30 μmol/L U0126可抑制毒染细胞R200增殖,与对照组相比具有统计学差异(P200组(R200L组)细胞形态发生变化,至第30代出现恶性转化,至第40代时恶性转化特征明显;而R200组细胞及U0126诱导的R200组(R200LU组)细胞则在第40代时才出现恶性转化特征。R200L组细胞凝集速度较R200LU组快,其余各组细胞P30出现凝集,且随ConA浓度增加,细胞凝集速度加快。R200L组细胞自P40可见克隆形成,克隆形成率为2.25‰±0.5‰,R200LU组及R200组未见克隆集落。R200L组细胞pERK表达增强;加入U0126阻断后,R200L组细胞pERK磷酸化水平降低。 Leptin可以促进云锡矿粉毒染肺上皮细胞的恶性转化,ERK信号通路可能是其促进云锡矿粉引发的肺泡II型上皮细胞转化的重要途径。
- 20 October 2023
- Vol. 26 (10) , 732-740
Open Access瘦素/ERK信号在云锡矿粉诱导大鼠II型肺泡上皮细胞转化中的作用
目前,云南个旧锡矿有大量矿工从事开采工作,这种职业环境与接触粉尘颗粒、重金属、多环芳烃和放射性氡有关,大大增加了患肺癌的风险。本研究旨在探讨在云锡矿粉诱导大鼠肺泡II型上皮细胞(immortalized rat alveolar cells type II, RLE-6TN)恶性转化过程中,瘦素(leptin)及其介导的细胞外调节蛋白激酶(extracellular regulated protein kinase, ERK)信号通路所起的作用。 采用200 μg/mL的云锡矿粉隔代毒染RLE-6TN至第9代,建立毒染细胞模型,命名为R200细胞,正常培养组命名为R细胞,通过Western blot法检测两种细胞leptin受体的表达情况。通过MTT法筛选出leptin及丝裂原活化蛋白激酶激酶(mitogen-activated protein kinase kinase, MEK)抑制剂(U0126)对R200细胞的最佳作用浓度。自第20代起,将R组、R200组细胞分别与leptin及MEK抑制剂U0126共培养,对各组细胞的形态改变进行观察,并利用苏木素-伊红(hematoxylin-eosin, HE)染色技术鉴别第40代细胞的形态学差异,通过刀豆凝集素A(concanavalin A, ConA)及锚着独立性生长实验法检测细胞恶性转化情况。通过Western blot法检测leptin作用后上皮细胞ERK信号通路的变化。 ng/mL时,其促增殖效应最为显著,30 μmol/L U0126可抑制毒染细胞R200增殖,与对照组相比具有统计学差异(P200组(R200L组)细胞形态发生变化,至第30代出现恶性转化,至第40代时恶性转化特征明显;而R200组细胞及U0126诱导的R200组(R200LU组)细胞则在第40代时才出现恶性转化特征。R200L组细胞凝集速度较R200LU组快,其余各组细胞P30出现凝集,且随ConA浓度增加,细胞凝集速度加快。R200L组细胞自P40可见克隆形成,克隆形成率为2.25‰±0.5‰,R200LU组及R200组未见克隆集落。R200L组细胞pERK表达增强;加入U0126阻断后,R200L组细胞pERK磷酸化水平降低。 Leptin可以促进云锡矿粉毒染肺上皮细胞的恶性转化,ERK信号通路可能是其促进云锡矿粉引发的肺泡II型上皮细胞转化的重要途径。